Nigel Liverton
Overview
Explore the profile of Nigel Liverton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer C, Garzia A, Miller M, Huggins D, Myers R, Hoffmann H, et al.
Nature
. 2024 Dec;
637(8048):1178-1185.
PMID: 39663451
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid development of highly effective vaccines against SARS-CoV-2 has altered the trajectory of the pandemic,...
2.
Sun S, Ginn J, Kochanczyk T, Arango N, Jiang X, Huggins D, et al.
Angew Chem Int Ed Engl
. 2024 Jul;
63(44):e202407276.
PMID: 38997232
Tuberculosis remains a leading cause of death from a single infection worldwide. Drug resistance to existing and even new antimycobacterials calls for research into novel targets and unexplored mechanisms of...
3.
Sun S, Fushimi M, Rossetti T, Kaur N, Ferreira J, Miller M, et al.
J Chem Inf Model
. 2024 Jan;
64(3):1106.
PMID: 38258980
No abstract available.
4.
Sun S, Fushimi M, Rossetti T, Kaur N, Ferreira J, Miller M, et al.
J Chem Inf Model
. 2023 Apr;
63(9):2828-2841.
PMID: 37060320
Free energy perturbation is a computational technique that can be used to predict how small changes to an inhibitor structure will affect the binding free energy to its target. In...
5.
Zhang H, Ginn J, Zhan W, Leung A, Liu Y, Toita A, et al.
J Med Chem
. 2023 Jan;
66(2):1484-1508.
PMID: 36630286
With increasing reports of resistance to artemisinins and artemisinin-combination therapies, targeting the proteasome is a promising strategy for antimalarial development. We recently reported a highly selective proteasome inhibitor with anti-malarial...
6.
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
Liu Y, Li Q, Alikarami F, Barrett D, Mahdavi L, Li H, et al.
Cancer Discov
. 2022 Sep;
12(11):2684-2709.
PMID: 36053276
Significance: AML is a poor-prognosis disease for which new therapeutic approaches are desperately needed. We developed an orally bioavailable inhibitor of ENL, demonstrated its potent efficacy in MLL-rearranged and NPM1-mutated...
7.
Kastan N, Oak S, Liang R, Baxt L, Myers R, Ginn J, et al.
Proc Natl Acad Sci U S A
. 2022 Jul;
119(28):e2206113119.
PMID: 35867764
The Hippo signaling pathway acts as a brake on regeneration in many tissues. This cascade of kinases culminates in the phosphorylation of the transcriptional cofactors Yap and Taz, whose concentration...
8.
Liang R, Tomita D, Sasaki Y, Ginn J, Michino M, Huggins D, et al.
ACS Med Chem Lett
. 2022 Mar;
13(3):377-387.
PMID: 35300079
Aberrant gene-silencing through dysregulation of polycomb protein activity has emerged as an important oncogenic mechanism in cancer, implicating polycomb proteins as important therapeutic targets. Recently, an inhibitor targeting EZH2, the...
9.
Ginn J, Jiang X, Sun S, Michino M, Huggins D, Mbambo Z, et al.
ACS Infect Dis
. 2021 Feb;
7(2):435-444.
PMID: 33527832
Tuberculosis remains a leading cause of death from a single bacterial infection worldwide. Efforts to develop new treatment options call for expansion into an unexplored target space to expand the...
10.
McComas C, Palani A, Chang W, Holloway M, Lesburg C, Li P, et al.
ChemMedChem
. 2017 Jul;
12(17):1436-1448.
PMID: 28741898
Studies directed at developing a broadly acting non-nucleoside inhibitor of HCV NS5B led to the discovery of a novel structural class of 5-aryl benzofurans that simultaneously interact with both the...